Colossal Biosciences Hits $30B Valuation | Tech News

Colossal Biosciences is on a funding tear, aiming for a $20–30 billion valuation—up from $10 billion just a year ago—as it starts generating revenue through government deals and a $60 million UAE investment. Beyond de-extinction, the company’s spinning off ventures in plastic breakdown and computational biology, while quietly developing artificial womb tech for fertility—targeting a 2025 launch. They’re also eyeing biodiversity credits as a future revenue stream, riding the wave of booming deep tech sectors like longevity and clean energy. This is one to watch. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f18e917ea84d745f